Polunovsky (23 results)

Author
Refine with Advanced Search

Refine your search

  • Books (23)

to

Custom price range (US$)

to

  • Language: English

    Published by Humana, 2010

    1603272704 / 9781603272704

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Hardcover

    Seller: Brook Bookstore On Demand, Napoli, NA, ItalyBrook Bookstore On Demand

    5-star seller
    Contact seller

    Condition: New

    US$ 96.59

    US$ 7.81 shipping 
    Ships from Italy to U.S.A.

    Quantity: 1 available

    Condition: new.

  • Language: English

    Published by Humana, 2010

    1603272704 / 9781603272704

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Hardcover

    Seller: Ria Christie Collections, Uxbridge, United KingdomRia Christie Collections

    5-star seller
    Contact seller

    Condition: New

    US$ 260.81

    US$ 15.12 shipping 
    Ships from United Kingdom to U.S.A.

    Quantity: Over 20 available

    Condition: New. In English.

  • Language: English

    Published by Humana, 2012

    1617796948 / 9781617796944

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Softcover

    Seller: Ria Christie Collections, Uxbridge, United KingdomRia Christie Collections

    5-star seller
    Contact seller

    Condition: New

    US$ 260.81

    US$ 15.12 shipping 
    Ships from United Kingdom to U.S.A.

    Quantity: Over 20 available

    Condition: New. In English.

  • More images

    Language: English

    Published by Humana, 2012

    1617796948 / 9781617796944

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Softcover

    Seller: preigu, Osnabrück, Germanypreigu

    5-star seller
    Contact seller

    Condition: New

    US$ 218.81

    US$ 80.40 shipping 
    Ships from Germany to U.S.A.

    Quantity: 5 available

    Taschenbuch. Condition: Neu. mTOR Pathway and mTOR Inhibitors in Cancer Therapy | Vitaly A. Polunovsky (u. a.) | Taschenbuch | Cancer Drug Discovery and Development | xii | Englisch | 2012 | Humana | EAN 9781617796944 | Verantwortliche Person für die EU: Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.

  • Language: English

    Published by Humana Press Inc., 2012

    1617796948 / 9781617796944

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Softcover

    Seller: Kennys Bookshop and Art Galleries Ltd., Galway, GY, IrelandKennys Bookshop and Art Galleries Ltd.

    5-star seller
    Contact seller

    Condition: New

    US$ 298.09

    US$ 10.91 shipping 
    Ships from Ireland to U.S.A.

    Quantity: 15 available

    Condition: New. Editor(s): Polunovsky, V. A.; Houghton, Peter J. Series: Cancer Drug Discovery and Development. Num Pages: 304 pages, 3 colour tables, biography. BIC Classification: MJCL; MMG; PSF. Category: (P) Professional & Vocational. Dimension: 235 x 155 x 17. Weight in Grams: 486. . 2012. Paperback. . . . .

  • Language: English

    Published by Humana Press Inc., 2010

    1603272704 / 9781603272704

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Hardcover

    Seller: Kennys Bookshop and Art Galleries Ltd., Galway, GY, IrelandKennys Bookshop and Art Galleries Ltd.

    5-star seller
    Contact seller

    Condition: New

    US$ 299.58

    US$ 10.91 shipping 
    Ships from Ireland to U.S.A.

    Quantity: 15 available

    Condition: New. Editor(s): Polunovsky, V. A.; Houghton, Peter J. Series: Cancer Drug Discovery and Development. Num Pages: 304 pages, 3 colour tables, biography. BIC Classification: MJCL. Category: (P) Professional & Vocational. Dimension: 235 x 155 x 23. Weight in Grams: 695. . 2010. Hardback. . . . .

  • Language: English

    Published by Humana Press, 2010

    1603272704 / 9781603272704

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Hardcover

    Seller: Buchpark, Trebbin, GermanyBuchpark

    5-star seller
    Contact seller

    Condition: Used - Fine

    US$ 187.29

    US$ 120.60 shipping 
    Ships from Germany to U.S.A.

    Quantity: 1 available

    Condition: Sehr gut. Zustand: Sehr gut | Seiten: 316 | Sprache: Englisch | Produktart: Bücher | The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment ¿ targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics.

  • Language: English

    Published by Humana Press, 2012

    1617796948 / 9781617796944

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Softcover

    Seller: Revaluation Books, Exeter, United KingdomRevaluation Books

    5-star seller
    Contact seller

    Condition: New

    US$ 349.76

    US$ 13.39 shipping 
    Ships from United Kingdom to U.S.A.

    Quantity: 2 available

    Paperback. Condition: Brand New. 316 pages. 9.25x6.10x0.75 inches. In Stock.

  • Language: English

    Published by Humana Pr Inc, 2010

    1603272704 / 9781603272704

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Hardcover

    Seller: Revaluation Books, Exeter, United KingdomRevaluation Books

    5-star seller
    Contact seller

    Condition: New

    US$ 351.41

    US$ 16.74 shipping 
    Ships from United Kingdom to U.S.A.

    Quantity: 2 available

    Hardcover. Condition: Brand New. 1st edition. 301 pages. 9.25x6.25x1.00 inches. In Stock.

  • Language: English

    Published by Humana Press Inc., 2012

    1617796948 / 9781617796944

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Softcover

    Seller: Kennys Bookstore, Olney, MD, U.S.A.Kennys Bookstore

    5-star seller
    Contact seller

    Condition: New

    US$ 354.94

    US$ 10.50 shipping 
    Ships within U.S.A.

    Quantity: 15 available

    Condition: New. Editor(s): Polunovsky, V. A.; Houghton, Peter J. Series: Cancer Drug Discovery and Development. Num Pages: 304 pages, 3 colour tables, biography. BIC Classification: MJCL; MMG; PSF. Category: (P) Professional & Vocational. Dimension: 235 x 155 x 17. Weight in Grams: 486. . 2012. Paperback. . . . . Books ship from the US and Ireland.

  • Language: English

    Published by Humana Press Inc., 2010

    1603272704 / 9781603272704

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Hardcover

    Seller: Kennys Bookstore, Olney, MD, U.S.A.Kennys Bookstore

    5-star seller
    Contact seller

    Condition: New

    US$ 356.71

    US$ 10.50 shipping 
    Ships within U.S.A.

    Quantity: 15 available

    Condition: New. Editor(s): Polunovsky, V. A.; Houghton, Peter J. Series: Cancer Drug Discovery and Development. Num Pages: 304 pages, 3 colour tables, biography. BIC Classification: MJCL. Category: (P) Professional & Vocational. Dimension: 235 x 155 x 23. Weight in Grams: 695. . 2010. Hardback. . . . . Books ship from the US and Ireland.

  • Language: English

    Published by Humana, 2010

    1603272704 / 9781603272704

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Hardcover

    Seller: Mispah books, Redhill, SURRE, United KingdomMispah books

    4-star seller
    Contact seller

    Condition: Used - As new

    US$ 383.55

    US$ 33.49 shipping 
    Ships from United Kingdom to U.S.A.

    Quantity: 1 available

    Hardcover. Condition: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

  • Condition: Used - Good

    US$ 199.00

    US$ 9.99 shipping 
    Ships within U.S.A.

    Quantity: 1 available

    Add to basket

    Hardcover. Condition: Good. In Russian. Polunovsky, Albert Grigorievich. Construction of vertical drainage piles in the construction of highways on weak ground. Moscow: 1974. All images are for identification of editions only. Several books of the same edition may be available. Please feel free to request photos of available books.SKU7329055.

  • Language: English

    Published by Humana, 2012

    1617796948 / 9781617796944

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Softcover
    • Print on Demand

    Seller: Brook Bookstore On Demand, Napoli, NA, ItalyBrook Bookstore On Demand

    5-star seller
    Contact seller

    Condition: New

    US$ 196.73

    US$ 6.32 shipping 
    Ships from Italy to U.S.A.

    Quantity: Over 20 available

    Condition: new. Questo è un articolo print on demand.

  • Language: English

    Published by Humana, 2010

    1603272704 / 9781603272704

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Hardcover
    • Print on Demand

    Seller: Brook Bookstore On Demand, Napoli, NA, ItalyBrook Bookstore On Demand

    5-star seller
    Contact seller

    Condition: New

    US$ 196.73

    US$ 7.81 shipping 
    Ships from Italy to U.S.A.

    Quantity: Over 20 available

    Condition: new. Questo è un articolo print on demand.

  • Language: English

    Published by Humana Press, 2012

    1617796948 / 9781617796944

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Softcover
    • Print on Demand

    Seller: moluna, Greven, Germanymoluna

    5-star seller
    Contact seller

    Condition: New

    US$ 213.03

    US$ 56.27 shipping 
    Ships from Germany to U.S.A.

    Quantity: Over 20 available

    Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding .

  • Language: English

    Published by Humana Press, 2010

    1603272704 / 9781603272704

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Hardcover
    • Print on Demand

    Seller: moluna, Greven, Germanymoluna

    5-star seller
    Contact seller

    Condition: New

    US$ 213.03

    US$ 56.27 shipping 
    Ships from Germany to U.S.A.

    Quantity: Over 20 available

    Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding .

  • Language: English

    Published by Humana Press Okt 2012, 2012

    1617796948 / 9781617796944

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Softcover
    • Print on Demand

    Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, GermanyBuchWeltWeit Ludwig Meier e.K.

    5-star seller
    Contact seller

    Condition: New

    US$ 253.16

    US$ 26.42 shipping 
    Ships from Germany to U.S.A.

    Quantity: 2 available

    Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment - targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics. 316 pp. Englisch.

  • Language: English

    Published by Humana Press Aug 2010, 2010

    1603272704 / 9781603272704

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Hardcover
    • Print on Demand

    Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, GermanyBuchWeltWeit Ludwig Meier e.K.

    5-star seller
    Contact seller

    Condition: New

    US$ 253.16

    US$ 26.42 shipping 
    Ships from Germany to U.S.A.

    Quantity: 2 available

    Buch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment - targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics. 316 pp. Englisch.

  • Language: English

    Published by Humana Press, Humana Aug 2010, 2010

    1603272704 / 9781603272704

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Hardcover
    • Print on Demand

    Seller: buchversandmimpf2000, Emtmannsberg, BAYE, Germanybuchversandmimpf2000

    5-star seller
    Contact seller

    Condition: New

    US$ 253.16

    US$ 68.92 shipping 
    Ships from Germany to U.S.A.

    Quantity: 1 available

    Buch. Condition: Neu. This item is printed on demand - Print on Demand Titel. Neuware -The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment ¿ targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics.Springer-Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 316 pp. Englisch.

  • Language: English

    Published by Humana Press, Humana Press Okt 2012, 2012

    1617796948 / 9781617796944

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Softcover
    • Print on Demand

    Seller: buchversandmimpf2000, Emtmannsberg, BAYE, Germanybuchversandmimpf2000

    5-star seller
    Contact seller

    Condition: New

    US$ 253.16

    US$ 68.92 shipping 
    Ships from Germany to U.S.A.

    Quantity: 1 available

    Taschenbuch. Condition: Neu. This item is printed on demand - Print on Demand Titel. Neuware -The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment ¿ targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics.Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin 316 pp. Englisch.

  • Language: English

    Published by Humana, 2012

    1617796948 / 9781617796944

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Softcover
    • Print on Demand

    Seller: AHA-BUCH GmbH, Einbeck, GermanyAHA-BUCH GmbH

    5-star seller
    Contact seller

    Condition: New

    US$ 352.17

    US$ 35.03 shipping 
    Ships from Germany to U.S.A.

    Quantity: 1 available

    Taschenbuch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment - targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics.

  • Language: English

    Published by Humana, 2010

    1603272704 / 9781603272704

    Series: Book 64 of 96 - Cancer Drug Discovery and Development

    • Hardcover
    • Print on Demand

    Seller: AHA-BUCH GmbH, Einbeck, GermanyAHA-BUCH GmbH

    5-star seller
    Contact seller

    Condition: New

    US$ 352.17

    US$ 35.03 shipping 
    Ships from Germany to U.S.A.

    Quantity: 1 available

    Buch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment - targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics.